A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL by Anthony R. Mato, Lindsey E. Roeker,

Slides:

Advertisements

Similar presentations

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

Advertisements

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Characterization and treatment of chronic active Epstein- Barr virus disease: a 28-year experience in the United States by Jeffrey I. Cohen, Elaine S.

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,

Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model by Neil A. Goldenberg, Alex C. Spyropoulos,

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide - Fludarabine.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)‏ by Nicolas.

Mechanisms of HIV-associated lymphocyte apoptosis

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

by Jessica A. Reese, Xiaoning Li, Manfred Hauben, Richard H

by Fangxin Hong, Thomas M Habermann, Leo I

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Primary testicular lymphoma

ROCK and Rho(ll) in bone marrow

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Patients’ priorities in selecting chronic lymphocytic leukemia treatments by Carol Mansfield, Anthony Masaquel, Jessie Sutphin, Elisa Weiss, Meghan Gutierrez,

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL by Arnon P. Kater, Sabina.

Anergy: the CLL cell limbo

Role of primacy of birth in HLA-identical sibling transplantation

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world.

Activity of eltrombopag in severe aplastic anemia

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD by Nelli Bejanyan, Claudio G. Brunstein,

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD by Gérard Socié, Noel Milpied, Ibrahim.

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB (Alliance)‏ by John C. Byrd, Amy S. Ruppert,

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in.

Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients by Erica B. Esrick, John P. Manis,

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Volume 2(Supplement 1):1-3

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Plasma biomarker concentrations between study groups.

by Christine L. Kempton, and Amanda B. Payne

Ontogeny of platelet function

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods by Mikhail Roshal, Juan A. Flores-Montero,

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia by Andrew Wei, Stephen.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking by Juliet N. Barker, Jane Kempenich, Joanne.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.

by Catherine Lai, Vishal Ranpura, Colin Wu, Matthew J. Olnes, Ankur R

Anti-CD20-IL-21 fusokine: the tail wags the dog

by Andrew L. Gilman, Michael J

Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)‏ by Laura Moreno, Aintzane.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

Initial treatment of CLL: integrating biology and functional status

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia by Susan M. O'Brien, Nicole Lamanna, Thomas.

Volume 2(Supplement 1):4-7

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed.

Presentation transcript:

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL by Anthony R. Mato, Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, Paul M. Barr, Frederick Lansigan, Bruce D. Cheson, Arun K. Singavi, Maryam Sarraf Yazdy, Nirav N. Shah, John N. Allan, Erica B. Bhavsar, Joanna Rhodes, Kaitlin Kennard, Stephen J. Schuster, AnnaLynn M. Williams, Alan P. Skarbnik, Andre H. Goy, Julie M. Goodfriend, Colleen Dorsey, Catherine C. Coombs, Hande Tuncer, Chaitra S. Ujjani, Ryan Jacobs, Allison M. Winter, John M. Pagel, Neil Bailey, Anna Schuh, Mazyar Shadman, Andrea Sitlinger, Hanna Weissbrot, Sivraj Muralikrishnan, Andrew Zelenetz, Amy A. Kirkwood, and Christopher P. Fox BloodAdv Volume 3(10):1568-1573 May 28, 2019 © 2019 by The American Society of Hematology

Anthony R. Mato et al. Blood Adv 2019;3:1568-1573 © 2019 by The American Society of Hematology

PFS and OS. PFS (A) and OS (B) stratified by VEN monotherapy (VENmono) and VEN plus anti-CD20 (VENcombo) in R/R CLL. PFS and OS. PFS (A) and OS (B) stratified by VEN monotherapy (VENmono) and VEN plus anti-CD20 (VENcombo) in R/R CLL. Anthony R. Mato et al. Blood Adv 2019;3:1568-1573 © 2019 by The American Society of Hematology